Cargando…

Serum WT1-271 IgM antibody as a novel diagnostic marker for Gastric Cancer

The Wilms tumor 1 gene, WT1, is overexpressed in various types of cancer, including gastric cancer. The product of WT1 is highly immunogenic and is a promising target molecule for cancer immunotherapy. The current study aimed to examine the production of WT1-specific IgG and IgM autoantibodies to id...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ito, Masaaki, Oji, Yusuke, Adachi, Mayuko, Imanishi, Rin, Alzaaqi, Shouq, Hiwasa, Takaki, Oshima, Yoko, Yajima, Satoshi, Suzuki, Takashi, Nanami, Tatsuki, Sumazaki, Makoto, Shiratori, Fumiaki, Funahashi, Kimihiko, Sugiayama, Haruo, Shimada, Hideaki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2022
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8848733/ https://www.ncbi.nlm.nih.gov/pubmed/35251625 http://dx.doi.org/10.3892/mco.2022.2507

Ejemplares similares

WT1 epitope-specific IgG and IgM antibodies for immune-monitoring in patients with advanced sarcoma treated with a WT1 peptide cancer vaccine
por: Alzaaqi, Shouq, et al.
Publicado: (2022)

High serum PD‐L1 level is a poor prognostic biomarker in surgically treated esophageal cancer
por: Ito, Masaaki, et al.
Publicado: (2019)

Preoperative Low Serum Calcium Levels Predict Poor Prognosis for Patients with Esophageal Cancer
por: Shiratori, Fumiaki, et al.
Publicado: (2021)

Is High Score of Preoperative Lactate Dehydrogenase to Albumin Ratio Predicting Poor Survivals in Esophageal Carcinoma Patients?
por: Shiratori, Fumiaki, et al.
Publicado: (2023)

Association of Serum Anti-PCSK9 Antibody Levels with Favorable Postoperative Prognosis in Esophageal Cancer
por: Ito, Masaaki, et al.
Publicado: (2021)

Diagnostic impact of high serum midkine level in patients with gastric cancer
por: Ito, Masaaki, et al.
Publicado: (2019)

Is high serum programmed death ligand 1 level a risk factor for poor survival in patients with gastric cancer?
por: Ito, Masaaki, et al.
Publicado: (2018)

The combination of positive anti‑WDR1 antibodies with negative anti‑CFL1 antibodies in serum is a poor prognostic factor for patients with esophageal carcinoma
por: Ito, Masaaki, et al.
Publicado: (2023)

Prevalence of serum galectin-1 autoantibodies in seven types of cancer: A potential biomarker
por: Nanami, Tatsuki, et al.
Publicado: (2021)

Randomized Phase II Study to Comparing Docetaxel/Nedaplatin versus Docetaxel for 5-Fluorouracil/Cisplatin Resistant Esophageal Squamous Cell Carcinoma
por: Yajima, Satoshi, et al.
Publicado: (2021)

Comparison between a new assay system, Elecsys(®) Anti-p53, and conventional MESACUP™ for the detection of serum anti-p53 antibodies: A multi-institutional study
por: Suzuki, Takashi, et al.
Publicado: (2022)

Cellular and Humoral Immune Responses Induced by an HLA Class I–restricted Peptide Cancer Vaccine Targeting WT1 Are Associated With Favorable Clinical Outcomes in Advanced Ovarian Cancer
por: Nishida, Sumiyuki, et al.
Publicado: (2022)

Association of WT1 IgG antibody against WT1 peptide with prolonged survival in glioblastoma multiforme patients vaccinated with WT1 peptide
por: Oji, Yusuke, et al.
Publicado: (2016)

Multipanel assay of 17 tumor‐associated antibodies for serological detection of stage 0/I breast cancer
por: Sumazaki, Makoto, et al.
Publicado: (2021)

WT1 Trio Peptide-Based Cancer Vaccine for Rare Cancers Expressing Shared Target WT1
por: Oji, Yusuke, et al.
Publicado: (2023)

Extremely strong infiltration of WT1-specific CTLs into mouse tumor by the combination vaccine with WT1-specific CTL and helper peptides
por: Nakata, Jun, et al.
Publicado: (2018)

Does Preoperative Low HbA1c Predict Esophageal Cancer Outcomes?
por: Kochi, Ryosuke, et al.
Publicado: (2019)

Identification of a Novel C-Terminal Truncated WT1 Isoform with Antagonistic Effects against Major WT1 Isoforms
por: Tatsumi, Naoya, et al.
Publicado: (2015)

WT1 Peptide Cancer Vaccine for Patients with Hematopoietic Malignancies and Solid Cancers
por: Oka, Yoshihiro, et al.
Publicado: (2007)

Prognostic significance of specific anti-WT1 IgG antibody level in plasma in patients with ovarian carcinoma
por: Andersson, Charlotta, et al.
Publicado: (2014)

Observations in 271 Cases of Mastoiditis
por: Calhoun, F. P.
Publicado: (1908)

Possible predictive significance of serum RalA autoantibodies on relapse-free survival in patients with colorectal cancer
por: Ushigome, Mitsunori, et al.
Publicado: (2021)

Expression of the Wilms' Tumor Gene WT1 in Solid Tumors and Its Involvement in Tumor Cell Growth
por: Oji, Yusuke, et al.
Publicado: (1999)

PMM no. 27.1 & 5.2
Publicado: (1981)

Decoding the Role of CD271 in Melanoma
por: Vidal, Anna, et al.
Publicado: (2020)

271 What Is the Cause Of This Patient’s Hypertension?
Publicado: (2020)

271. Fungal Diagnostic Studies in Histoplasmosis
por: Krishnan, Gayathri, et al.
Publicado: (2019)

Health Tract, No. 271: Intemperate Women
Publicado: (1867)

271 Diagnosis and Detection of Thrombosis in PCOS
por: Miller, Mariel, et al.
Publicado: (2023)

Mcdst 70-271 exam cram 2
por: Balter, Dan
Publicado: (2004)

AB271. Sexual dysfunction in chronic prostatitis
por: Cho, In-Rae
Publicado: (2016)

Syndecan-4 as a biomarker to predict clinical outcome for glioblastoma multiforme treated with WT1 peptide vaccine
por: Takashima, Satoshi, et al.
Publicado: (2016)

IMT-07 CLINICAL TRIAL OF A COCKTAIL WILMS’ TUMOR 1 (WT1) VACCINATION USING TWO HLA CLASS I PEPTIDES AND ONE CLASS II PEPTIDE FOR RECURRENT MALIGNANT GLIOMAS
por: Kagawa, Naoki, et al.
Publicado: (2019)

The Wilms' Tumor Gene WT1 − 17AA/− KTS Splice Variant Increases Tumorigenic Activity Through Up-Regulation of Vascular Endothelial Growth Factor in an In Vivo Ovarian Cancer Model
por: Yamanouchi, Keiko, et al.
Publicado: (2014)

Encouraging Clinical Evolution of a Pediatric Patient With Relapsed Diffuse Midline Glioma Who Underwent WT1-Targeting Immunotherapy: A Case Report and Literature Review
por: Hashii, Yoshiko, et al.
Publicado: (2020)

Al Cern temperatura record, meno 271o
por: Ponzi, Luca
Publicado: (2007)

CD271 is an imperfect marker for melanoma initiating cells
por: Cheli, Yann, et al.
Publicado: (2014)

271 Evaluation of Adverse Events Associated to Administration of Omalizumab
por: Gomez, R. Maximiliano, et al.
Publicado: (2012)

CD271 determines migratory properties of melanoma cells
por: Radke, Josefine, et al.
Publicado: (2017)

P271 A masquerading case of Cryptococcus neoformans
por: S, Divyashree, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_fk7dsi2e4b3dveib0o686qlfnf